NextCure (NASDAQ:NXTC) Upgraded to Buy at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of NextCure (NASDAQ:NXTC) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat reports. LADENBURG THALM/SH SH currently has $18.00 price objective on the stock.

NXTC has been the subject of several other reports. Piper Sandler set a $15.00 price objective on shares of NextCure and gave the stock an “overweight” rating in a research note on Tuesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NextCure presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

NextCure Price Performance

Shares of NASDAQ NXTC traded down $0.86 during mid-day trading on Friday, hitting $8.96. 21,236 shares of the company’s stock traded hands, compared to its average volume of 86,194. NextCure has a 1 year low of $2.69 and a 1 year high of $19.20. The company’s 50-day moving average is $7.29 and its two-hundred day moving average is $6.08. The company has a market capitalization of $24.01 million, a P/E ratio of -0.37 and a beta of 1.48.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, topping the consensus estimate of ($4.06) by $0.84. Equities analysts anticipate that NextCure will post -1.87 EPS for the current fiscal year.

Institutional Trading of NextCure

A hedge fund recently raised its stake in NextCure stock. Pfizer Inc boosted its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 29.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,891,763 shares of the company’s stock after purchasing an additional 433,213 shares during the quarter. NextCure comprises about 0.2% of Pfizer Inc’s portfolio, making the stock its 17th biggest position. Pfizer Inc owned 6.74% of NextCure worth $909,000 at the end of the most recent reporting period. 42.65% of the stock is currently owned by institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.